Studies have shown that drugs used in the treatment of breast cancer - compounds containing anthracyclines - cause the development of myelocytic leukemia and myelodysplastic syndrome, according to the Internet publication for girls and women from 14 to 35 years old Pannochka. net A large number of drugs are used for the therapy of breast cancer. The mode and dose of drugs depends on the severity and stage of the disease. However, in all cases, at present, the main ones are preparations containing anthracyclines.

According to the National Surgical Congress devoted to the therapy of cancer of the intestine and breast, the risk of development of therapy-related diseases (leukemia) is directly proportional to the dose and intensity of therapy. In patients who, in addition to chemotherapy, receive radiotherapy, a lower risk of comorbidities has been identified, writes Dr. Smith R.

In patients receiving a strengthened course of chemotherapy, requiring the introduction of certain hormonal factors (G-CSF), the risk is further increased. Scientists associate this additional risk increase, specifically with the hormonal component of therapy. Scientists have also shown that the risk increases depending on the intensity of therapy, rather than on the total (accumulated) dose of drugs medicus. En.